Skip to main content
Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
101.14
+2.22 (2.24%)
Apr 24, 2025, 4:00 PM EDT - Market closed

Boston Scientific Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Cardiology
8.90B 8.35B 7.80B 7.32B 6.97B 6.71B 6.49B 6.32B
Cardiology Growth
27.65% 24.40% 20.24% 15.81% 13.75% 13.08% 11.35% 11.08%
Endoscopy
2.72B 2.69B 2.64B 2.59B 2.55B 2.48B 2.41B 2.34B
Endoscopy Growth
6.67% 8.22% 9.68% 10.86% 12.35% 11.75% 9.06% 7.15%
Peripheral Interventions
2.49B 2.41B 2.30B 2.23B 2.18B 2.11B 2.05B 1.99B
Peripheral Interventions Growth
14.41% 14.27% 11.99% 12.09% 12.55% 11.12% 8.92% 7.32%
Urology
2.32B 2.20B 2.10B 2.05B 2.01B 1.96B 1.91B 1.86B
Urology Growth
15.54% 12.02% 9.56% 9.87% 9.79% 10.77% 10.19% 10.43%
Neuromodulation
1.12B 1.11B 1.08B 1.04B 998.00M 976.00M 956.00M 948.00M
Neuromodulation Growth
12.22% 13.22% 12.45% 9.28% 5.83% 6.32% 4.71% 3.83%

Revenue by Geography
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
10.91B 10.21B 9.53B 9.04B 8.68B 8.43B 8.20B 8.03B
United States Growth
25.71% 21.19% 16.25% 12.49% 10.49% 10.40% 10.14% 11.03%
EMEA
3.27B 3.23B 3.15B 3.05B 2.95B 2.86B 2.76B 2.68B
EMEA Growth
11.03% 13.06% 13.90% 13.75% 12.70% 13.02% 9.17% 5.56%
APAC
2.74B 2.69B 2.62B 2.54B 2.50B 2.40B 2.32B 2.24B
APAC Growth
9.56% 11.83% 12.75% 13.47% 16.50% 13.52% 8.56% 5.61%
LACA
631.00M 625.00M 618.00M 605.00M 583.00M 560.00M 534.00M 507.00M
LACA Growth
8.23% 11.61% 15.73% 19.33% 19.71% 19.66% 17.88% 17.09%

Operating Expense Breakdown
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Selling, General, and Administrative
6.22B 5.98B 5.75B 5.43B 5.34B 5.19B 4.97B 4.86B
Selling, General, and Administrative Growth
16.45% 15.30% 15.62% 11.66% 14.20% 14.82% 10.29% 9.45%
Research and Development
1.69B 1.62B 1.52B 1.47B 1.44B 1.42B 1.38B 1.37B
Research and Development Growth
17.24% 14.20% 9.91% 7.55% 7.68% 6.95% 5.26% 6.31%
Amortization
862.00M 857.00M 840.00M 843.00M 840.00M 829.00M 820.00M 814.00M
Amortization Growth
2.62% 3.38% 2.44% 3.56% 3.96% 3.24% 3.02% 4.63%
Asset and Goodwill Impairment
- 387.00M - 277.00M - - 58.00M 182.00M
Asset and Goodwill Impairment Growth
- - - 52.20% - - -82.37% -45.18%
Royalty Expense
38.00M 34.00M 36.00M 42.00M 45.00M 46.00M 47.00M 47.00M
Royalty Expense Growth
-15.56% -26.09% -23.40% -10.64% -2.17% -2.13% 4.44% -2.08%
Restructuring Net Charges
23.00M 16.00M 31.00M 38.00M 53.00M 70.00M 57.00M 46.00M
Restructuring Net Charges Growth
-56.60% -77.14% -45.61% -17.39% 29.27% 180.00% 35.71% -2.13%
Litigation-related Net Charges
- - - - - - 20.00M -
Contingent Consideration Net Expense
-17.00M -5.00M 10.00M 45.00M 62.00M 57.00M 10.00M 18.00M
Contingent Consideration Net Expense Growth
- - - 150.00% 77.14% 62.86% -80.00% 350.00%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.